Kintara Therapeutics Inc
For the period ended Jun 30, 2024. Filed Oct 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Oct 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
On July 31, 2019, Marcum LLP (“Marcum”), Certified Public Accountants, were appointed as our auditors.
The following is a summary of fees paid by us for professional services rendered by Marcum for the years ended June 30, 2024, and 2023.
| Year EndedJune 30,2024 | Year EndedJune 30,2023 | |
|---|---|---|
| Audit Fees | $476,100 | $264,525 |
| Audit-Related Fees | 21,248 | 42,610 |
| Tax Fees | — | — |
| All Other Fees | — | — |
| Total Fees | $497,348 | $307,135 |
Audit fees. Audit fees represent fees for professional services performed by Marcum for the audit of our annual financial statements and the review of our quarterly financial statements, as well as services that are normally provided in connection with statutory and regulatory filings or engagements.
Audit-related fees. Audit-related fees represent fees for assurance and related services performed by Marcum that are reasonably related to the performance of the audit or review of our financial statements.
Tax Fees. Marcum has not performed any tax compliance services for us during the years ended June 30, 2024, or 2023.
All other fees. Marcum has not received any other fees from us for the years ended June 30, 2024, or 2023.
In accordance with applicable laws, rules and regulations, our audit committee charter and pre-approval policies established by the audit committee require that the audit committee review in advance and pre-approve all audit and permitted non-audit fees for services provided to us by our independent registered public accounting firm. The services performed by, and the fees to be paid to, Marcum in 2024, and 2023, respectively, were approved by the audit committee.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.